Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, ...
Mar 21, 2022
0
44
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile, ...
Jan 5, 2022
0
56
A combination of two drugs keeps patients with chronic lymphocytic leukemia disease-free and alive longer than the current standard of care, according to a phase-3 clinical trial of more than 500 participants conducted at ...
Jul 31, 2019
0
108
A new treatment that may extend survival for patients with advanced biliary tract cancers—who typically face a grim outlook with average survival of less than a year—is being studied by a University of Arizona Cancer ...
Jul 30, 2019
0
43
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma.
Jun 6, 2019
0
135
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy improved progression-free survival (PFS) in patients ...
Aug 5, 2024
0
1
Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of ...
Aug 5, 2024
0
0
Second- or third-line treatment with tisotumab vedotin is efficacious for patients with recurrent cervical cancer, according to a study published in the New England Journal of Medicine.
Jul 8, 2024
0
0
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment, according to a study published ...
Jul 1, 2024
0
0
The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is the third FDA-approved ...
Jun 24, 2024
0
0
